Business Description
Bristol-Myers Squibb Co
NAICS : 325412
SIC : 2834
ISIN : ARDEUT112877
Share Class Description:
BUE:BMY: CedearDescription
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.17 | |||||
| Equity-to-Asset | 0.17 | |||||
| Debt-to-Equity | 3.48 | |||||
| Debt-to-EBITDA | 10.79 | |||||
| Interest Coverage | 5.58 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 1.23 | |||||
| Beneish M-Score | -2.92 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 4.8 | |||||
| 3-Year EBITDA Growth Rate | 62.2 | |||||
| 3-Year EPS without NRI Growth Rate | 5.3 | |||||
| 3-Year FCF Growth Rate | 1.1 | |||||
| 3-Year Book Growth Rate | -5.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate | -4.45 | |||||
| Future 3-5Y Total Revenue Growth Rate | -1 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 21.23 | |||||
| 9-Day RSI | 26.94 | |||||
| 14-Day RSI | 31.1 | |||||
| 6-1 Month Momentum % | 24.01 | |||||
| 12-1 Month Momentum % | 80.92 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.11 | |||||
| Quick Ratio | 0.99 | |||||
| Cash Ratio | 0.37 | |||||
| Days Inventory | 86.16 | |||||
| Days Sales Outstanding | 67.49 | |||||
| Days Payable | 104.78 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.81 | |||||
| Dividend Payout Ratio | 16.67 | |||||
| 3-Year Dividend Growth Rate | 7.9 | |||||
| Forward Dividend Yield % | 2.81 | |||||
| 5-Year Yield-on-Cost % | 4.14 | |||||
| 3-Year Average Share Buyback Ratio | 3.1 | |||||
| Shareholder Yield % | 6.75 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 75.71 | |||||
| Operating Margin % | 15.98 | |||||
| Net Margin % | -13.5 | |||||
| FCF Margin % | 26.6 | |||||
| ROE % | -22.16 | |||||
| ROA % | -6.5 | |||||
| ROIC % | 9.31 | |||||
| ROC (Joel Greenblatt) % | -57.79 | |||||
| ROCE % | -6.27 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 6.44 | |||||
| PE Ratio without NRI | 13.13 | |||||
| Shiller PE Ratio | 36.17 | |||||
| PEG Ratio | 0.54 | |||||
| PS Ratio | 2.02 | |||||
| PB Ratio | 5.51 | |||||
| Price-to-Free-Cash-Flow | 7.35 | |||||
| Price-to-Operating-Cash-Flow | 6.7 | |||||
| EV-to-EBIT | -30.52 | |||||
| EV-to-Forward-EBIT | 10.3 | |||||
| EV-to-EBITDA | 26.06 | |||||
| EV-to-Forward-EBITDA | 7.7 | |||||
| EV-to-Revenue | 3.04 | |||||
| EV-to-Forward-Revenue | 3.02 | |||||
| EV-to-FCF | 11.08 | |||||
| Price-to-Projected-FCF | 0.65 | |||||
| Price-to-DCF (Earnings Based) | 0.46 | |||||
| Price-to-DCF (FCF Based) | 0.24 | |||||
| Price-to-Median-PS-Value | 0.52 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.87 | |||||
| Earnings Yield (Greenblatt) % | -3.28 | |||||
| FCF Yield % | 13.76 | |||||
| Forward Rate of Return (Yacktman) % | 27.87 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Bristol-Myers Squibb Co Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ARS) | 20,671,251.458 | ||
| EPS (TTM) (ARS) | -4085.201 | ||
| Beta | 0 | ||
| Volatility % | 48.52 | ||
| 14-Day RSI | 31.1 | ||
| 14-Day ATR (ARS) | 466.31777 | ||
| 20-Day SMA (ARS) | 17558.875 | ||
| 12-1 Month Momentum % | 80.92 | ||
| 52-Week Range (ARS) | 9940 - 22442.5 | ||
| Shares Outstanding (Mil) | 2,027.1 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Bristol-Myers Squibb Co Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Bristol-Myers Squibb Co Stock Events
| Event | Date | Price(ARS) | ||
|---|---|---|---|---|
| No Event Data | ||||
Bristol-Myers Squibb Co Frequently Asked Questions
What is Bristol-Myers Squibb Co(BUE:BMY)'s stock price today?
The current price of BUE:BMY is ARS16245.50. The 52 week high of BUE:BMY is ARS22442.50 and 52 week low is ARS9940.00.
When is next earnings date of Bristol-Myers Squibb Co(BUE:BMY)?
The next earnings date of Bristol-Myers Squibb Co(BUE:BMY) is 2024-07-26.
Does Bristol-Myers Squibb Co(BUE:BMY) pay dividends? If so, how much?
The Dividend Yield %  of Bristol-Myers Squibb Co(BUE:BMY) is 2.81% (As of Today), Highest Dividend Payout Ratio of Bristol-Myers Squibb Co(BUE:BMY) was 16.67. The lowest was 0.27. And the median was 0.38. The  Forward Dividend Yield % of Bristol-Myers Squibb Co(BUE:BMY) is 2.81%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers